REVA Medical Highlights Successful MOTIV® Demonstration and BTK Trial Results at VIVA26
In a significant medical advance, REVA Medical, LLC, recently held a live demonstration of its innovative MOTIV® bioresorbable vascular stent during the Vascular InterVentional Advances (VIVA) 2026 conference in Las Vegas, Nevada. This demonstration underscored the stent's capabilities and aligned with the latest clinical trial findings that underline its effectiveness in treating critical limb-threatening ischemia (CLTI).
The presentation was led by Dr. Andrej Schmidt from Leipzig University Hospital, who performed a groundbreaking procedure on a 72-year-old female patient suffering from severe chronic limb-threatening ischemia, classified as Rutherford Category 5. The patient's condition included a non-healing ulcer, prompting the need for a sophisticated medical intervention.
In this live operation, Dr. Schmidt successfully employed two MOTIV® stents, one measuring 4.0 mm x 48 mm and the other 3.5 mm x 24 mm. The procedure achieved successful revascularization of the patient's under-the-knee peripheral artery, yielding excellent angiographic results, which were broadcasted to all attendees at the conference.
Moreover, the event also featured a presentation by Dr. Ehrin Armstrong from HCA Health One Swedish Medical Center in Denver. His analysis dealt with sub-group data from the pivotal MOTIV trial, focusing on the clinical outcomes of patients categorized as Rutherford 4 and 5. This multi-centered clinical trial involved 292 participants, showcasing a complex patient demographic, with 69% classified as level 5 on the Rutherford scale.
In the sub-group analysis from the MOTIV trial, results demonstrated a composite measure favoring MOTIV® stenting compared to standard balloon angioplasty (PTA) both at the 6-month and 12-month marks across all Rutherford categories. At 6 months, the composite endpoint was met by 87.2% of patients treated with MOTIV® in the Rutherford 4 category, compared to 76.3% for those using PTA. For Rutherford 5 patients, the respective rates were 77.0% for MOTIV® and 55.8% for PTA. At the one-year checkpoint, those numbers further improved for the MOTIV® group, establishing a clear efficacy when set against PTA.
Furthermore, during the acute phase of treatment, MOTIV® displayed superior technical and procedural success rates compared to PTA, particularly pronounced within the more complex Rutherford 5 cohort.
Jeffrey Anderson, the CEO of REVA Medical, expressed enthusiasm about the live case demonstration and the outcomes reported from the MOTIV trial, asserting their commitment to addressing the needs of patients with complex below-the-knee lesions. He stated, "The success of this procedure and the consistent clinical results observed in both Rutherford category 4 and 5 patients underscore our dedication to improving patient treatments in critical vascular conditions."
The implications of these advancements are substantial, particularly for patients suffering from hischémie chronique sévère, which is the most critical form of peripheral artery disease (PAD) often leading to intense pain, non-healing wounds, and even amputation. The MOTIV® stent is specifically designed to remove blockages and support vessels during healing without leaving a permanent implant, thus revolutionizing treatment methodologies for vascular ailments.
In conclusion, REVA Medical not only showcased a successful operation but reaffirmed its position at the forefront of vascular treatment technology at VIVA26, focusing on their commitment to develop innovative solutions for complex medical conditions. As they continue to pave the way in the realm of bioresorbable technology, the medical community watches closely, eager for further breakthroughs that may enhance patient outcomes significantly.
The presentation was led by Dr. Andrej Schmidt from Leipzig University Hospital, who performed a groundbreaking procedure on a 72-year-old female patient suffering from severe chronic limb-threatening ischemia, classified as Rutherford Category 5. The patient's condition included a non-healing ulcer, prompting the need for a sophisticated medical intervention.
In this live operation, Dr. Schmidt successfully employed two MOTIV® stents, one measuring 4.0 mm x 48 mm and the other 3.5 mm x 24 mm. The procedure achieved successful revascularization of the patient's under-the-knee peripheral artery, yielding excellent angiographic results, which were broadcasted to all attendees at the conference.
Moreover, the event also featured a presentation by Dr. Ehrin Armstrong from HCA Health One Swedish Medical Center in Denver. His analysis dealt with sub-group data from the pivotal MOTIV trial, focusing on the clinical outcomes of patients categorized as Rutherford 4 and 5. This multi-centered clinical trial involved 292 participants, showcasing a complex patient demographic, with 69% classified as level 5 on the Rutherford scale.
In the sub-group analysis from the MOTIV trial, results demonstrated a composite measure favoring MOTIV® stenting compared to standard balloon angioplasty (PTA) both at the 6-month and 12-month marks across all Rutherford categories. At 6 months, the composite endpoint was met by 87.2% of patients treated with MOTIV® in the Rutherford 4 category, compared to 76.3% for those using PTA. For Rutherford 5 patients, the respective rates were 77.0% for MOTIV® and 55.8% for PTA. At the one-year checkpoint, those numbers further improved for the MOTIV® group, establishing a clear efficacy when set against PTA.
Furthermore, during the acute phase of treatment, MOTIV® displayed superior technical and procedural success rates compared to PTA, particularly pronounced within the more complex Rutherford 5 cohort.
Jeffrey Anderson, the CEO of REVA Medical, expressed enthusiasm about the live case demonstration and the outcomes reported from the MOTIV trial, asserting their commitment to addressing the needs of patients with complex below-the-knee lesions. He stated, "The success of this procedure and the consistent clinical results observed in both Rutherford category 4 and 5 patients underscore our dedication to improving patient treatments in critical vascular conditions."
The implications of these advancements are substantial, particularly for patients suffering from hischémie chronique sévère, which is the most critical form of peripheral artery disease (PAD) often leading to intense pain, non-healing wounds, and even amputation. The MOTIV® stent is specifically designed to remove blockages and support vessels during healing without leaving a permanent implant, thus revolutionizing treatment methodologies for vascular ailments.
In conclusion, REVA Medical not only showcased a successful operation but reaffirmed its position at the forefront of vascular treatment technology at VIVA26, focusing on their commitment to develop innovative solutions for complex medical conditions. As they continue to pave the way in the realm of bioresorbable technology, the medical community watches closely, eager for further breakthroughs that may enhance patient outcomes significantly.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.